Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Parabilis Medicines closed its upsized initial public offering, selling 38.5 million shares at $20.00 per share for gross proceeds of $770.5 million. The offering included the full exercise of the underwriters' option and a concurrent private placement of 4.17 million shares to Regeneron Pharmaceuticals at $18.00 per share, raising an additional $75 million.
Key figures
- Offering Price
- 20
- Shares Offered
- 38525000
- Ipo gross proceeds
- 770500000
- Safe conversion amount
- 50000000
- Private placement proceeds
- 75000000
- Concurrent private placement price
- 18
- Concurrent private placement shares
- 4166666
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.